A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII's preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency.

Institute of Biotechnology of the Czech Academy of Sciences BIOCEV Prumyslova 595 252 50 Vestec Czech Republic

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Flemingovo nám 2 Prague 6 166 10 Czech Republic

Institute of Organic Chemistry Research Centre for Natural Sciences Hungarian Academy of Sciences 1117 Budapest Magyar Tudósok körútja 2 Hungary

Johns Hopkins Drug Discovery Johns Hopkins University Baltimore MD 21205 United States

Johns Hopkins Drug Discovery Johns Hopkins University Baltimore MD 21205 United States; Department of Molecular and Comparative Pathobiology Johns Hopkins University Baltimore MD 21205 United States

Johns Hopkins Drug Discovery Johns Hopkins University Baltimore MD 21205 United States; Department of Neurology Johns Hopkins University Baltimore MD 21205 United States

McDaniel College 2 College Hill Westminster MD 21157 United States

Zobrazit více v PubMed

Zhou J, Neale JH, Pomper MG, et al., NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov 2005;4:1015–1026. PubMed

Ferraris DV, Shukla K, Tsukamoto T, Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors. Curr. Med. Chem 2012;19:1282–1294. PubMed

Vornov JJ, Hollinger KR, Jackson PF, et al., Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors. Adv Pharmacol. 2016;76:215–255. PubMed

Eiber M, Fendler WP, Rowe SP, et al., Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med. 2017;58:67S–76S. PubMed

Rais R, Jiang W, Zhai H, et al., FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI Insight. 2016;1. PubMed PMC

Kozikowski AP, Nan F, Conti P, et al., Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J. Med. Chem 2001;44:298–301. PubMed

Kozikowski AP, Zhang J, Nan F, et al., Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J. Med. Chem 2004;47:1729–1738. PubMed

Olszewski RT, Bukhari N, Zhou J, et al., NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem. 2004;89:876–885. PubMed

Mease RC, Dusich CL, Foss CA, et al., N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036–3043. PubMed PMC

Olszewski RT, Wegorzewska MM, Monteiro AC, et al., Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry. 2008;63:86–91. PubMed PMC

Yamamoto T, Kozikowski A, Zhou J, et al., Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Molecular pain. 2008;4:31. PubMed PMC

Zhang AX, Murelli RP, Barinka C, et al., A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 2010;132:12711–12716. PubMed PMC

Feng JF, Van KC, Gurkoff GG, et al., Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. Brain Res. 2011;1395:62–73. PubMed PMC

Kratochwil C, Giesel FL, Eder M, et al., [(1)(7)(7)Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987–988. PubMed

Yang X, Mease RC, Pullambhatla M, et al., [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA). J Med Chem. 2016;59:206–218. PubMed PMC

Klusak V, Barinka C, Plechanovova A, et al., Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. Biochemistry. 2009;48:4126–4138. PubMed PMC

Mlcochova P, Plechanovova A, Barinka C, et al., Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. FEBS J. 2007;274:4731–4741. PubMed

Plechanovova A, Byun Y, Alquicer G, et al., Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. J Med Chem. 2011;54:7535–7546. PubMed PMC

Slusher BS, Rojas C, Coyle JT, Chapter 367 - Glutamate Carboxypeptidase II A2 - Rawlings, Neil D, in: Salvesen G (Ed.) Handbook of Proteolytic Enzymes, Academic Press; 2013, pp. 1620–1627.

Barinka C, Byun Y, Dusich CL, et al., Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008;51:7737–7743. PubMed PMC

Kopka K, Benesova M, Barinka C, et al., Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J Nucl Med. 2017;58:17S–26S. PubMed

Gutten O, Bim D, Rezac J, et al., Macrocycle Conformational Sampling by DFT-D3/COSMO-RS Methodology. J Chem Inf Model. 2018;58:48–60. PubMed

Mesters JR, Barinka C, Li W, et al., Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006;22:1375–1384. PubMed PMC

Pavlicek J, Ptacek J, Barinka C, Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme. Curr Med Chem. 2012;19:1300–1309. PubMed

Buck SB, Huff JK, Himes RH, et al., Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24. J Med Chem. 2004;47:3697–3699. PubMed

Wiesner M, Neff B, Method for the production of bicyclic aromatic amino acids and intermediate products thereof, US 7,371,854, 2008.

Conway RE, Rojas C, Alt J, et al., Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis. 2016;19:487–500. PubMed

Hlouchova K, Barinka C, Konvalinka J, et al., Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. FEBS J. 2009;276:4448–4462. PubMed

Kabsch W, Xds. Acta Crystallogr D Biol Crystallogr. 2010;66:125–132. PubMed PMC

Murshudov GN, Skubak P, Lebedev AA, et al., REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67:355–367. PubMed PMC

Emsley P, Lohkamp B, Scott WG, et al., Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486–501. PubMed PMC

Schuttelkopf AW, van Aalten DM, PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004;60:1355–1363. PubMed

Chen VB, Arendall WB 3rd, Headd JJ, et al., MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12–21. PubMed PMC

Navratil M, Tykvart J, Schimer J, et al., Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities. FEBS J. 2016;283:2528–2545. PubMed

Sparta M, Neese F, Chemical applications carried out by local pair natural orbital based coupled-cluster methods. Chem Soc Rev. 2014;43:5032–5041. PubMed

Neese F, The ORCA program system. WIREs Comput Mol Sci. 2012;2:73–78.

Klamt A, Conductor-like Screening Model for Real Solvents: A New Approach to the Quantitative Calculation of Solvation Phenomena. J. Phys. Chem 1995;99:2224–2235.

Klamt A, Jonas V, Börger T, et al., Refinement and Parametrization of COSMO-RS. J. Phys. Chem 1998;102:5074–5085.

Eichkorn K, Treutler O, Öhm H, et al., Auxiliary basis sets to approximate Coulomb potentials. Chem. Phys. Lett 1995;240:283–290.

Grimme S, Antony J, Ehrlich S, et al., A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J Chem Phys. 2010;132:154104. PubMed

Klamt A, Schüürmann G, COSMO: a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J. Chem. Soc. Perkin Trans. 2 1993:799–805.

Tao J, Perdew JP, Staroverov VN, et al., Climbing the density functional ladder: nonempirical meta-generalized gradient approximation designed for molecules and solids. Phys Rev Lett. 2003;91:146401. PubMed

Combination of In Silico and In Vitro Screening to Identify Novel Glutamate Carboxypeptidase II Inhibitors

Ligand Strain and Its Conformational Complexity Is a Major Factor in the Binding of Cyclic Dinucleotides to STING Protein